Connect with us

Healthcare

Visualizing What COVID-19 Does to Your Body

Published

on

View the full-size version of this infographic.

what covid-19 does to your body
what covid-19 does to your body

Visualizing What COVID-19 Does to Your Body

View the high resolution version of this infographic by clicking here

By now, researchers and health experts have gained a better understanding of the range of symptoms caused by COVID-19, which include fever, a dry cough, and of course, the dangerous inflammation of the respiratory system. Most of us know that COVID-19 can be much more severe than a typical flu, but lesser known are the mechanics behind how the virus causes pneumonia in its victims.

Today’s informative illustration, by scientific designer and animator Avesta Rastan, details the effects COVID-19 has on our lungs, from moderate to severe cases.

According to the World Health Organization (WHO), most people who contract COVID-19 only experience mild flu-like symptoms. Occasionally though, the infection can cascade into a severe case of pneumonia that can be lethal, especially for older people and those with underlying medical conditions.

Here’s what COVID-19 does to your body.

Infection

The virus, officially named SARS-CoV-2, enters the body – generally through the mouth or nose. From there, the virus makes its way down into the air sacs inside your lungs, known as alveoli.

Once in the alveoli, the virus uses its distinctive spike proteins to “hijack” cells. The primary genetic programming of any virus is to make copies of itself, and COVID-19 is no exception. Once the virus’ RNA has entered a cell, new copies are made and the cell is killed in the process, releasing new viruses to infect neighboring cells in the alveolus.

This process can occur initially without a person being aware of the infection, which is one of the reasons COVID-19 has been able to spread so effectively.

Immune Response

The process of hijacking cells to reproduce causes inflammation in the lungs, which triggers an immune response. As this process unfolds, fluid begins to accumulate in the alveoli, causing a dry cough and making breathing difficult.

For 80-85% of people infected by COVID-19, these symptoms will run their course much as they would with a case of the flu.

Severe Symptoms

In 15-20% cases, the immune system’s response to inflammation in the lungs can cause what’s known as a “cytokine storm”. This runaway response can cause more damage to the body’s own cells than to the virus it’s trying to defeat, and is thought to be the main reason for why the conditions of young, otherwise healthy individuals can rapidly deteriorate.

If enough alveoli collapse, a patient to be placed on a ventilator for breathing assistance. Both acute respiratory distress syndrome (ARDS) and high-altitude pulmonary edema (HAPE) are being investigated as causes.

severe case of covid-19

At this stage, the surfactant that helps keep alveoli from collapsing has been diluted, and fluid containing cellular debris is impairing the gas exchange process that supplies oxygen to our bloodstream.

In the most severe cases, systemic inflammatory response syndrome (SIRS) occurs as the protein-rich fluid from the lungs enters the bloodstream, resulting in septic shock and multi-organ failure. This is often the cause of death for people who have succumbed to a COVID-19 infection.

The Best Protection

Thankfully, COVID-19 isn’t a death sentence for most people who become infected, but the symptoms described above are not pleasant. Until a vaccine is developed, the best defense is avoiding infection altogether through frequent, thorough hand washing, and physical distancing as recommended by health authorities.

To see the full set of graphics, as well as other health and science related illustrations, visit Avesta Rastan’s website.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Comments

Healthcare

Visualizing Global Attitudes Towards the COVID-19 Vaccines

This graphic visualizes global attitudes to vaccines categorized into five segments including anti-vaxxers and COVID cautious.

Published

on

Visualizing Global Attitudes Towards COVID-19 Vaccines

View the high-resolution of the infographic by clicking here.

To vaccinate, or not to vaccinate? That is the question.

In order to achieve herd immunity against COVID-19, some experts believe that between 70% to 80% of a population must be vaccinated.

But attitudes towards these vaccines are undoubtedly mixed. In fact, it’s estimated that one-third of people globally have some major concerns.

Using survey data from eight different countries, Global Web Index created five archetypes to help illustrate how typical attitudes towards vaccines differ depending on a range of factors, such as age, income, lifestyle, and values.

SegmentBreakdownAge SkewGender SkewIncomeVaccine Concerns
Vaccine Supporter66%18-34NoneHigh incomePotential side-effects, availability, and logistics of vaccine distribution.
Vaccines Hesitant12%38-56FemaleLow/Middle incomePotential side-effects specifically due to no long-term testing, cost of vaccine, and more transparency around science required.
Vaccine Obligated11%16-24MaleLow incomePotential side-effects, not sure COVID-19 vaccine is necessary to combat the virus.
Vaccine Skeptical11%45-64FemaleLow incomePotential side-effects, don’t believe vaccines can curtail the pandemic.
Anti-vaxxer1.4% (13% of the Vaccine Skeptical segment)16-24, 55-64MaleLow incomePotential side-effects, don’t believe vaccines in general are safe.

Countries surveyed: United States, Germany, United Kingdom, Brazil, China, India, Japan, and Italy.

Which segment are you most likely to fall under, according to these segments?

Vaccine Supporters

[People who say they will get the COVID-19 vaccine.]

Out of all participants surveyed, 66% of them support the idea of getting a COVID-19 vaccine. Within this group, there is a skew towards younger people (aged 18-34) who are likely working professionals earning a high income and living in a city.

Despite their optimism towards COVID-19 vaccines, however, one-third of vaccine supporters say they will wait to get one, due to lingering concerns regarding issues with vaccine distribution and any potential side-effects.

Interestingly, this procrastination mindset has been seen before during the H1N1 (swine flu) pandemic when both members of the general public and healthcare workers showed low levels of vaccine acceptance due to safety concerns.

Vaccine Hesitant

[People who are not sure if they will get the COVID-19 vaccine.]

The vaccine hesitant group, which is more common among cautious suburban parents, makes up 12% of the total study. They are more likely to be female, and feel anxious about the length of time spent testing vaccines and therefore require more transparency around the science.

With that being said, this group could be easily swayed, as they are more receptive to word-of-mouth and messaging boards to get advice from their peers over any other medium.

Vaccine Obligated

[People who will only get the vaccine if it’s necessary for travel, school, work etc.]

The vaccine obligated group makes up 11% of the total, and has a skew towards males aged between 16 and 24 years old.

While this group is also concerned with potential side-effects, their responses suggesting that a vaccine may not be necessary to combat COVID-19 was above average compared to other segments in the study. They also index above average when it comes to viewing themselves as traditionalists.

Vaccine Skeptical

[People who won’t get the COVID-19 vaccine.]

The vaccine skeptical group makes up another 11% of the total. However, this group is mostly female, who are aged between 45-64 and earn a lower-than-average income. They are less likely to have a college degree, and are more likely to live in a rural area.

Along with the worry of potential side-effects, this group is generally more pessimistic about containing COVID-19 at all. Therefore a small percentage do not believe a vaccine will help tackle the global health crisis.

With notably low trust levels, this group is one of the hardest to reach and potentially persuade. What makes them unique however, is their lack of faith in the scientific process.

Anti-Vaxxers

[People who will not get the vaccine, because they are against vaccines in general.]

It is important to note that those who choose not to get a COVID-19 vaccine should not be confused with anti-vaxxers.

Anti-vaxxers are a sub-segment of the vaccine skeptical group that makes up 1.4% of the total population. The difference is, anti-vaxxers do not believe in getting any vaccine due to safety concerns, not just not a vaccine for COVID-19.

According to the study, anti-vaxxers tend to fall into one of two age brackets, between 16-24 years or 55-64 years old, and are typically males with lower incomes.

Another Tool in the Arsenal Against COVID-19

The study demonstrates that broad segments of society—regardless of their demographic or views—are at least somewhat concerned about COVID-19 vaccines becoming widely available.

While scientists are not quite sure if the current vaccines on the market can stop infection or transmission of the virus, they are an important part of our global defenses against COVID-19, along with other safety restrictions like wearing masks and keeping a distance.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Markets

9 Things Investors Should Know About the Cannabis Industry in 2021

This graphic provides an overview of 9 key developments in the cannabis industry that investors should be aware of going into 2021.

Published

on

9 Things Cannabis Investors Should Know in 2021

Unlike dozens of other industries across the globe, cannabis experienced significant growth as a result of the COVID-19 pandemic.

In fact, with consumption for both medical and recreational products on the rise, 2020 was a record-breaking year for the industry. After years of investor uncertainty, analysts are predicting a continued bull market in 2021, with several new and exciting developments on the horizon.

Here are nine things cannabis investors need to know.

1. Cannabis Stocks on the Rise

While asset prices took a dip during the initial stage of the COVID-19 outbreak in March, the cannabis sector recovered swiftly after reporting impressive numbers.

Even though cannabis investors have experienced some ups and downs in the last several years, 2021 looks more hopeful.

2. COVID-19 and Cannabis

Cannabis has become an attractive option for people spending more time at home, both as a means of entertainment, and to reduce stress and anxiety associated with the pandemic.

As a result, cannabis sales are soaring. In Canada, monthly sales reached an all-time high of $270 million (CAD) in October 2020, a dramatic increase from $180 million just six months earlier.

3. Cannabis Black Market No More?

For millions of U.S. citizens who live in states where the sale of cannabis is still restricted, the illicit market continues to be their only option.

But with loosening restrictions and legal cannabis becoming more widely available, legal sales are predicted to reach $50 billion by 2026 while illegal sales will plummet to less than $1 billion by the same year.

YearU.S. Legal Cannabis SalesU.S. Illegal Cannabis Sales
2016$6 billion$25 billion
2026$50 billion<$1 billion

4. Political Change Driving Market Growth

Almost 70% of Americans now support the full legalization of cannabis—the highest figure ever recorded.

States where cannabis is legal are now paving the way for cannabis sales, with California expected to pull in over $6 billion by 2021 alone. If federal legalization comes to fruition over the next several years, the already booming U.S. market could see further growth.

5. All Eyes on the European Cannabis Market

The European cannabis market has been on investors’ radar for several years, and with good reason—it is one of the largest cannabis markets in the world.

Driven primarily by medicinal products, the market will be valued at over $39 billion by 2024, with countries like Germany—Europe’s largest economy—leading the way.

In late 2020, the market experienced its biggest breakthrough yet, with the European Union ruling that products containing CBD (one of the most active ingredients in cannabis) are no longer listed as narcotics.

6. Making History in Mexico

Mexico is another market that is piquing the interest of investors and cannabis companies the world over. That’s because it could soon be the third country in the world to legalize recreational cannabis by court order.

With a total addressable market of $2 billion and the potential to support up to 75,000 jobs, these new regulations could change the dynamic of the global market for the better.

7. Most Popular Cannabis Products

Given the flurry of product innovation in the market, consumption of cannabis is quickly changing.

Relatively new products such as edibles and oils are gaining traction, while consumption of flower appears to be declining. This could be due in part to oral products being perceived as a healthier alternative to smoking.

8. CBD Products are Moving into the Mainstream

Although CBD was once considered a niche product that could only be found in dispensaries, growing awareness of the benefits and safety of these products are causing companies operating in the consumer packaged goods industry to take notice.

The cannabis compound is a new addition to a wide range of products such as skincare, makeup, and supplements that can now be purchased almost anywhere—from ecommerce sites to local grocery stores.

9. The New Cannabinoids on the Block

Beyond CBD, scientists have discovered over 100 rare, or minor cannabinoids such as CBG and CBN, that could have even more significant benefits than their major cannabinoid counterparts.

For example, preliminary research shows that CBG could inhibit cancer growth, help treat glaucoma, bladder dysfunction, and kill drug-resistant bacteria.

These discoveries are not only attracting huge attention from the cannabis industry, but from the pharmaceutical industry as well.

Milestones in the Making

With all of these exciting developments coming to the fore, it’s safe to say 2021 could be one of the cannabis industry’s most transformative years to date.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Subscribe

Join the 230,000+ subscribers who receive our daily email

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Popular